Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex agrees to buy Crinetics for $85 per share in cash, about $10.0 billion

Neutral Impact 5 of 5 m&a Written later

Vertex Pharmaceuticals signed a merger agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a equity valuation of $10.0 billion ($8.8 billion net of cash). The deal is unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval and other conditions. Vertex plans to fund it with cash on hand and a $4.5 billion bridge loan, and it is not conditioned on financing.

Key points

  • Merger consideration: $85.00 per Crinetics share in cash, with unvested equity awards accelerated
  • Expected close in the third quarter of 2026; Vertex says 2026 guidance will be updated at closing
  • Termination fee payable by Crinetics in specified circumstances: $350,474,425
  • Financing: $4.5 billion unsecured 364-day bridge loan from Bank of America, BofA Securities and Morgan Stanley Senior Funding

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECJul 6, 2026, 9:55 PM ET
Accession number0001193125-26-296710

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.